

[Guardant, PathGroup partner to expand access to Shield test](#)

written by CAP TODAY
September 8, 2025

Sept. 8, 2025—Guardant Health and PathGroup are partnering to expand access to Guardant’s FDA-approved Shield blood test.



©2026 CAP TODAY, all rights reserved.

[RNA-Based Fusion Testing in Oncology: A Live Virtual Panel on NRG1 Fusions-November 5, 2025](#)

written by CAP TODAY
September 8, 2025



Webinar presenters **Wei Zhang, MD, PhD**, Medical Director of Molecular Pathology (Solid Tumor),

University of Kansas, and **Tejas Patil, MD**, Thoracic Medical Oncologist, UCHHealth, University of Colorado, discuss RNA testing practices and pathogenic gene fusions testing, with special focus on NRG1 fusions testing and management.



©2026 CAP TODAY, all rights reserved.

[Agilent expands Dako Omnis family](#)

written by CAP TODAY
September 8, 2025


Sept. 5, 2025—Agilent Technologies has introduced three models to its Dako Omnis family of instruments—the Omnis 110, 165, and 165 Duo—designed to provide laboratories with the flexibility to tailor staining solutions according to volume, workflow, and diagnostic requirements.



©2026 CAP TODAY, all rights reserved.

[Introduction of a new FDA approved rapid NGS solution for Companion Diagnostics and tumor profiling in oncology-August 27, 2025](#)

written by CAP TODAY
September 8, 2025



Webinar presenters **David Chi, PhD**, Director of Oncology Product Management, Thermo Fisher Scientific, and **Gary Pestano, PhD**, Chief Development Officer, Biodesix, Inc., and **Bence Sipos, MD**, Molecular Pathology, Baden-Württemberg, Stuttgart, Germany, discusses the rapidly evolving field of precision oncology, the increasing availability of targeted treatments offers renewed hope to patients.



©2026 CAP TODAY, all rights reserved.

[Data on the utility of MeMed BV to be presented at ACEP25](#)

written by CAP TODAY
September 8, 2025

Sept. 4, 2025—MeMed announced that several oral presentations at the American College of Emergency Physicians Scientific Assembly 2025, Sept. 7-10 in Salt Lake City, will showcase clinical evidence supporting the utility of MeMed BV, an FDA-cleared test that distinguishes between bacterial and viral infections based on the body's immune response.

[Qiagen launches QIAstat-Dx Rise](#)

written by CAP TODAY
September 8, 2025

Sept. 2, 2025—Qiagen has launched QIAstat-Dx Rise, a version of the QIAstat-Dx automated syndromic testing system.

[Optimal Molecular Results with Automated BOM Fixation & Decalcification](#)

written by CAP TODAY
September 8, 2025



Discover LeanDECAL, a groundbreaking instrument that streamlines both fixation and decalcification of bone marrow—improving molecular results by utilizing EDTA and boosting consistency, quality, and efficiency for laboratories. [Learn More.](#)



©2026 CAP TODAY, all rights reserved.

[Tempus AI acquires Paige](#)

written by CAP TODAY
September 8, 2025

Aug. 28, 2025—Tempus AI is acquiring Paige for \$81.25 million.



©2026 CAP TODAY, all rights reserved.

[Randox Labs expands its operations in West Virginia](#)

written by CAP TODAY
September 8, 2025

Aug. 27, 2025—Randox Laboratories plans to expand its facility in Jefferson County, W. Va., from a 48-person sales and distribution operation to a full-scale production laboratory.



©2026 CAP TODAY, all rights reserved.

SehaMed, New Day Dx to launch ColoHealth in the Middle East

written by CAP TODAY
September 8, 2025

Aug. 26, 2025—SehaMed Global (Bristol, England) announced a strategic distribution agreement with New Day Diagnostics, of Knoxville, Tenn., to bring ColoHealth, an FDA-approved blood test for the early detection of colorectal cancer, to patients in Saudi Arabia, the United Arab Emirates, and other countries in the Middle East.



©2026 CAP TODAY, all rights reserved.